{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=insulin+regular+IV+infusion&page=2",
    "query": {
      "intervention": "insulin regular IV infusion",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 106,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=insulin+regular+IV+infusion&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=insulin+regular+IV+infusion&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T00:32:29.001Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02930044",
      "title": "Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetic Ketoacidosis"
      ],
      "interventions": [
        {
          "name": "Early administration of subcutaneous insulin glargine dose",
          "type": "OTHER"
        },
        {
          "name": "IV insulin infusion",
          "type": "OTHER"
        },
        {
          "name": "IV fluid repletion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 18,
      "start_date": "2016-10",
      "completion_date": "2021-11-01",
      "has_results": false,
      "last_update_posted_date": "2022-04-01",
      "last_synced_at": "2026-10-02T00:32:29.001Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02930044"
    },
    {
      "nct_id": "NCT02321111",
      "title": "The Role of TLR4 on Lipid-induced Insulin Resistance",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Insulin Sensitivity"
      ],
      "interventions": [
        {
          "name": "Eritoran",
          "type": "DRUG"
        },
        {
          "name": "D5W (5% Dextrose in water)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 10,
      "start_date": "2015-01",
      "completion_date": "2018-09",
      "has_results": true,
      "last_update_posted_date": "2019-10-08",
      "last_synced_at": "2026-10-02T00:32:29.001Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02321111"
    },
    {
      "nct_id": "NCT02982551",
      "title": "Insulin Modulation of fMRI Connectivity in Healthy Adults",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Insulin",
          "type": "DRUG"
        },
        {
          "name": "Taste Task",
          "type": "OTHER"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "OTHER"
        },
        {
          "name": "Dextrose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "21 Years to 30 Years"
      },
      "enrollment_count": 0,
      "start_date": "2016-01-01",
      "completion_date": "2017-12",
      "has_results": false,
      "last_update_posted_date": "2017-12-04",
      "last_synced_at": "2026-10-02T00:32:29.001Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02982551"
    },
    {
      "nct_id": "NCT02371226",
      "title": "Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mucopolysaccharidosis I"
      ],
      "interventions": [
        {
          "name": "AGT-181 (HIRMAb-IDUA)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ArmaGen, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2015-07",
      "completion_date": "2017-02-01",
      "has_results": false,
      "last_update_posted_date": "2023-02-21",
      "last_synced_at": "2026-10-02T00:32:29.001Z",
      "location_count": 6,
      "location_summary": "Oakland, California • Orange, California • Decatur, Georgia + 3 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02371226"
    },
    {
      "nct_id": "NCT00845039",
      "title": "A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colon Cancer",
        "Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "Cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "IMC-A12 (cixutumumab)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2009-05",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2018-07-02",
      "last_synced_at": "2026-10-02T00:32:29.001Z",
      "location_count": 3,
      "location_summary": "Vallejo, California • Greenville, North Carolina • Scranton, Pennsylvania",
      "locations": [
        {
          "city": "Vallejo",
          "state": "California"
        },
        {
          "city": "Greenville",
          "state": "North Carolina"
        },
        {
          "city": "Scranton",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00845039"
    },
    {
      "nct_id": "NCT00460499",
      "title": "Improving Outcomes In Diabetic Patients During CABG Surgery By Optimizing Glycemic Control",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glycemic Control"
      ],
      "interventions": [
        {
          "name": "A IV Insulin drip",
          "type": "DRUG"
        },
        {
          "name": "B Low Dose GIK",
          "type": "DRUG"
        },
        {
          "name": "C High Dose GIK",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "American Heart Association",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 250,
      "start_date": "2004-07",
      "completion_date": "2015-03",
      "has_results": false,
      "last_update_posted_date": "2015-06-23",
      "last_synced_at": "2026-10-02T00:32:29.001Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00460499"
    },
    {
      "nct_id": "NCT00673309",
      "title": "Assessment of Mechanisms of Improved Wound Healing",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Burns"
      ],
      "interventions": [
        {
          "name": "Stable Isotope Infusion study",
          "type": "PROCEDURE"
        },
        {
          "name": "Insulin High Dose",
          "type": "DRUG"
        },
        {
          "name": "oxandrolone",
          "type": "DRUG"
        },
        {
          "name": "Propranolol",
          "type": "DRUG"
        },
        {
          "name": "Growth Hormone",
          "type": "DRUG"
        },
        {
          "name": "Insulin Low Dose",
          "type": "DRUG"
        },
        {
          "name": "IGF-1/IGFBP-3",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        },
        {
          "name": "Growth Hormone and Propranolol",
          "type": "DRUG"
        },
        {
          "name": "Oxandrolone and Propranolol",
          "type": "DRUG"
        },
        {
          "name": "Placebo or Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "The University of Texas Medical Branch, Galveston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "Up to 90 Years"
      },
      "enrollment_count": 644,
      "start_date": "2000-07",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2023-07-03",
      "last_synced_at": "2026-10-02T00:32:29.001Z",
      "location_count": 1,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00673309"
    },
    {
      "nct_id": "NCT02936687",
      "title": "Mechanisms of Cerebrovascular Control",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metabolic Syndrome X"
      ],
      "interventions": [
        {
          "name": "NOS Inhibition",
          "type": "DRUG"
        },
        {
          "name": "ET-1 Inhibition",
          "type": "DRUG"
        },
        {
          "name": "NOS Inhibition Placebo",
          "type": "DRUG"
        },
        {
          "name": "3 Tesla MRI",
          "type": "DEVICE"
        },
        {
          "name": "Intravenous Catheter",
          "type": "DEVICE"
        },
        {
          "name": "Oral Glucose Tolerance Test",
          "type": "OTHER"
        },
        {
          "name": "ET-1 Inhibition Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 59,
      "start_date": "2017-01-31",
      "completion_date": "2021-09-30",
      "has_results": false,
      "last_update_posted_date": "2021-10-18",
      "last_synced_at": "2026-10-02T00:32:29.001Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02936687"
    },
    {
      "nct_id": "NCT07167693",
      "title": "Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diabetes (DM)",
        "Diabetic Ketoacidosis",
        "Ketosis Prone Diabetes",
        "Hyperglycaemia (Diabetic)"
      ],
      "interventions": [
        {
          "name": "Arginine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Sodium Chloride 0.9%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "David K Carroll",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2025-12-19",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-12",
      "last_synced_at": "2026-10-02T00:32:29.001Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07167693"
    },
    {
      "nct_id": "NCT00690066",
      "title": "PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus",
        "Type 1 Diabetes",
        "Diabetes Mellitus, Insulin-Dependent",
        "Juvenile Diabetes"
      ],
      "interventions": [
        {
          "name": "PROCHYMAL®",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mesoblast, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "12 Years to 35 Years"
      },
      "enrollment_count": 63,
      "start_date": "2008-06-11",
      "completion_date": "2011-12-19",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-10-02T00:32:29.001Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Stanford, California + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00690066"
    }
  ]
}